Professional Documents
Culture Documents
DIAGNOSTICO SOSPECHA
• Recuento de CD4+ < 300 cel.
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
TRATAMIENTO PARA CANDIDIASIS ORAL:
Fluconazol 150-200 mg 5-7 días
-Alternativas:
Nistatina 5-7 días
Anfotericina B, suspensión oral 1-2 g qid 7-14 días
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
CANDIDIASIS ESOFAGICA
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
TRATAMIENTO PARA CANDIDIASIS ESOFAGICA
Fluconazol 400 mg/dia 3 días o 400 mg (1er dia) , 200 mg/dia por 10-14 días
-Si tras 7 días de tratamiento no se consigue la mejoría, se recomienda descartar otros microorganismos o resistencia a azoles.
ENFERMEDAD REFRACTARIA:
Posaconazol 400 mg /dia o Voriconazol 200 mg , 2 veces al dia.
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
PROFILAXIS SECUNDARIA :
No recomendada?
-Se puede emplear fluconazol 3 veces por semana.
En caso de recidivas muy frecuentes se debería sospechar resistencia a
azoles.
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
PNEUMOCYSTIS JIROVECII
• TOS
DIAGNOSTICO SOSPECHA • DISNEA DE ESFUERZO
• FIEBRE
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
TRATAMIENTO
TMP-SMX : 5mg/kg TMP IV/VO + 25 mg/kg SMX durante 21 días (tid) +
PREDNISONA ( pacientes con enfermedad moderada/grave (pO2 <70 mmhg o gradiente alveolo-
capilar >35 mmhg) Preferentemente 30 min antes del tratameinto.
PROFILAXIS SECUNDARIA :
-Siempre indicada en pacientes con neumonia previa
DETENER: Si CD4 >200 cel y CV indetectable durante mas de 3 meses
TMP-SMX: 800/160 mg 3x/semana o 400/80 mg por dia VO
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
PROFILAXIS PRIMARIA:
-Linfocitos CD4+ < 200 cel o candidiasis orofaringea previa
-Porcentaje de linfocitosCD4+ <14%
-Enfermedad previa definitoria de SIDA
DETENER: Si CD4 > 200 cel, durante al menos 3 meses o si CD4 están entre 100-200 con
CV indetectable durante mas de 3 meses.
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
COCCIDIOMICOSIS
Beaman LV, Pappagianis D, Benjamini E. Mechanisms of resistance to infection with Coccidioides immitis in mice. Infect Immun 1979; 23:681
Antoniskis D, Larsen RA, Akil B, et al. Seronegative disseminated coccidioidomycosis in patients with HIV infection. AIDS 1990; 4:691.
TRATAMIENTO
ENFERMEDAD MODERADA:
-ALTERNATIVAS: Itraconazol
ENFERMEDAD SEVERA SIN COMPROMISO RESPIRATORIO:
Iniciar terapia con anfotericina B y luego pasar a fluconazol (400 a 800 mg PO al día) o itraconazol (200 mg dos veces al día) cuando esté
estable por lo menos 12 meses.
Suspensión del tratamiento:
-Recuento de células CD4 es> 250 células / microL y no hay evidencia de
infección coccidioidal activa
-Título de fijación del complemento coccidioidal <1
• Microscopia positiva
DIAGNOSTICO • Detección del antígeno en LCR y en suero
CONFIRMATORIO • Cultivo de LCR
INDUCCION:
Anfotericina B liposomal 3mg/kg (qd + flucitosina 25mg/kg (qid) durante al menos 2 semanas
+
CONSOLIDACION
Fluconazol 400 mg (qd) VO POR 8 SEMANAS
+
PROFILAXIS SECUNDARIA
Fluconazol 200 mg (qd) VO por al menos 12 meses
--Considerar detener si el recuento de CD4 > 100 CEL Y VC es indetectable durante al menos 3 meses
CRYPTOCOCCUS NEOFORMANS
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
HISTOPLASMOSIS
1. Muraosa Y, Toyotome T, Yahiro M, et al. Detection of Histoplasma capsulatum from clinical specimens by cycling probe-based real-time PCR and nested real-time PCR. Med Mycol 2016;
54:433
2. Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997;
24:1169
HISTOPLASMA CAPSULATUM
TRATAMIENTO
Forma grave diseminada :
INDUCCION: Anfotericina liposomal 3mg/kg / qd 2 semanas
CONSOLIDACION: Itraconazol 200 mg tid, durante 12 meses.
Meningitis:
INDUCCION: Anfotericina liposomal 5mg/kg / qd 4-6 semanas
CONSOLIDACION: Itraconazol 200 mg tid, durante 12 meses.
1. Muraosa Y, Toyotome T, Yahiro M, et al. Detection of Histoplasma capsulatum from clinical specimens by cycling probe-based real-time PCR and nested real-time PCR. Med Mycol 2016;
54:433
2. Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997;
24:1169
PROFILAXIS SECUNDARIA
SIEMPRE, tras 12 meses de tratamiento. Se puede suspender con cifras de CD4+ > 150 cel durante al menos 6 meses, Carga
Viral indetectable y antígeno en suero <2 ng/Ml.
Itraconazol o fluconazol
1. Muraosa Y, Toyotome T, Yahiro M, et al. Detection of Histoplasma capsulatum from clinical specimens by cycling probe-based real-time PCR and nested real-time PCR. Med Mycol 2016;
54:433
2. Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997;
24:1169
MYCOBACTERIUM TUBERCULOSIS
• Perdida de peso
DIAGNOSTICO SOSPECHA • Fiebre vespertina
• Sudores nocturnos
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com
2.Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the
human immunodeficiency virus (updated January 2015). 2020.
Se indica el tratamiento de la infección tuberculosa a todos los pacientes con una prueba de la
tuberculina positiva (≥ 5 mm de induración) o con antecedente de la misma, independientemente
del recuento de linfocitos CD4+,
1.2019 E. EACS Guidelines version 10.0 (Nov 2019) .EACS Guidelines. 2020. https://eacs.sanfordguide.com